文献リスト

1) Hamada K, Hirayama M, Watanabe H, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I- MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003; 74: 423-6

2) Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005; 76: 249-51

3) Saiki S, Hirose G, Sakai K, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci. 2004; 15: 105-11

4) Suzuki M, Urashima M, Oka H, et al. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. Neuro Report. 2007; 18: 1867-70

5) Spiegel J, Hellwig D, Farmakis G, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord. 2007; 22: 1004-8

6) Kim JS, Lee KS, Song IU, et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci. 2008; 270: 122-6

7) Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006; 67: 2236-8

8) Oguri T, Tachibana N, Mitake S, et al. Decrease in myocardial (123)I-MIBG radioactivity in REM sleep behavior disorder: Two patients with different clinical progression. Sleep Med. 2008; 9: 583-5

9) Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorders in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology. 1996; 46: 388-93

10) Lee PH, Yeo SH, Kim HJ, et al. Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord. 2006; 78: 1975-7

11) Lee PH, Yeo SH, Yong SW, et al. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2007; 78: 1250-2

12) Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of neurodegenerative disease. Curr Neurol Neurosci Rep. 2006; 6: 379-86

13) Matsui H, Nishinaka K, Oda M, et al. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms？ Parkinsonism Relat Disord. 2006; 12: 284-8

14) Kamiyama M, Wada-Isoe K, Irizawa Y, et al. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. J Neurol Sci. 2008; 264: 22-6

15) Koyama S, Tachibana N, Masaoka Y, et al. Decreased myocardial (123)I-MIBG uptake and impaired facial expression recognition in a patient with REM sleep behavior disorder. Mov Disord. 2007; 22: 746-7

16) Goldstein DS, Sharabi Y, Karp BI, et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007; 17: 118-21

17) Spiegel J, Mollers MO, Jost WH, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 2005; 20: 552-61

18) Shindo K, Kaneko E, Watanabe H, et al. Analysis of the relationship between muscle sympathetic nerve activity and cardiac 123I-metaiodobenzylguanidine uptake in patients with Parkinson's disease. Mov Disord. 2005; 20: 1419-24

19) Hori N, Takamori M, Hirayama M, et al. Pupillary supersensitivity and isual disturbance in Parkinson's disease. Clin Auton Res. 2008; 18: 20-7

20) Kollensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord. 2007; 22: 1771-6

21) 土井英樹, 新井由紀, 長谷川康博, 他. Parkinson病における123I-MIBG心筋シンチグラフィと起立負荷試験の関連性. 臨床神経. 2008; 48: 56-9

22) Kajimoto Y, Miwa H, Okawa-Izawa M, et al. Transcranial sonography of the substantia nigra and MIBG myocardial scintigraphy: Complementary role in the diagnosis of Parkinson's disease. Parkinsonism Relat Disord. In press

23) Nakamura T, Hirayama M, Ito H, et al. Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci. 2007; 263: 133-8

24) Lee PH, Kim JW, Bang OY, et al. Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Mov Disord. 2006; 21: 1235-8

25) Kim JS, Lee PH, Lee KS, et al. Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. Mov Disord. 2006; 21: 1990-4

26) Kashihara K, Ohno M, Kawada S, et al. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med. 2006; 47: 1099-101

27) Li S-T, Dendi R, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann Neurol. 2002; 52: 220-3

28) Orimo S. MIBG Myocardial scintigraphy in the early diagnosis of Parkinson's disease. CNS Drug 2007; 21: 11-5

29) Suzuki M, Hattori N, Orimo S, et al. Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report. Mov Disord. 2005; 20: 634-6

30) Orimo S, Amino T, Yokochi M, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord. 2005; 20: 1350-3

31) Quattrone A, Bagnato A, Annesi G, et al. Myocardial 123I-metaiodobenzylguanidine uptake in genetic Parkinson's disease. Mov Disord. 2008; 23: 21-7

32) 荻野 裕, 荻野美恵子, 滝山洋子, 他. PARK8とParkinson病におけるMIBG心筋シンチグラフィーの比較[会]. 臨床神経. 2004; 44: 1185

33) Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon41 in Parkinson's disease patients from 18 countries. Mov Disord. 2006; 21: 1102-28

34) Goldstein DS, Imrich R, Peckham E, et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. Neurology. 2007; 69: 1580-4

35) Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005; 128: 2786-96

36) Singleton A, Gwinn-Hardy K, Sharabi Y, et al. Association between cardiac denervation and parkinsonism caused byα-synuclein gene triplication. Brain. 2004; 127: 768-72

37) Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity ofα-synuclein gene duplication in Parkinson's disease. Ann Neurol. 2006; 59: 298-309

38) Itokawa K, Tamura N, Kawai N, et al. Parkinsonism in type I Gaucher's disease. Intern Med. 2006; 45: 1165-7

39) Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006; 66: 1850-4

40) Suzuki M, Kurita A, Hashimoto M, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci. 2006; 240: 15-9

41) Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006; 33: 248-53

42) Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007; 260: 33-7

43) Oide T, Tokuda T, Momose M, et al. Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med. 2003; 42: 686-90

44) Hanyu H, Shimizu S, Hirao K, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord. 2006; 22: 379-84

45) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211

46) Braak H, de Vos RA, Bohl J, et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006; 396: 67-72

47) Bloch A, Probst A, Bissig H, et al. α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006; 32: 284-95

48) Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 2007; 17: 24-30

49) Okada Y, Ito Y, Aida J, et al. Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int. 2004; 54: 682-7

50) Fujishiro H, Frigerio R, Burnett M, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Diord 2008; 23: 1085-92

51) Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Doα-synuclein aggregates in autonomic plexuses predate Lewy body disorders？: a cohort study. Neurology. 2007; 68: 2012-8

52) Amino T, Orimo S, Itoh Y, et al. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005; 15: 29-34

53) Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 2005; 109: 583-8

54) Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodo-benzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006; 15; 243: 101-4

55) 氏家幸子, 荻野 裕, 織茂智之, 他. 遺伝性Parkinson病相模原家系(PARK8)の中枢神経病理所見と心臓交感神経の関係. 第49回日本神経学会総会プログラム・抄録集. 2008; 323

56) Wakabayashi K, Hayashi S, Ishikawa A, et al. Autosomal dominant diffuse Lewy body disease. Acta Neuropathol. 1998; 96: 207-10

57) Ikeuchi T, Kakita A, Shiga A, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol. 2008; 65: 514-9

58) Orimo S, Uchihara T, Nakamura A, et al. Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol. 2008; 116: 575-7

59) Orimo S, Uchihara T, Nakamura A, et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson disease. Brain. 2008; 131: 642-50

60) Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med. 2000; 41: 71-7

61) Takatsu H, Wada H, Maekawa N, et al. Significant reduction of 125I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl Med Commun. 2002; 23: 161-6

62) Fukumitsu N, Suzuki M, Fukuda T, et al. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism. Nucl Med Biol. 2006; 33: 37-42

63) Amino T, Uchihara T, Tsunekawa H, et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci Res. 2008; 60: 314-8

64) Orimo S, Kanazawa T, Nakamura A, et al. Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol. 2007; 113: 81-6

65) 饗場郁子, 斉藤由扶子, 伊藤信二, 他. Parkinson病を合併した進行性核上性麻痺の1剖検例. Neuropathol (suppl). 2005; 124

66) Nagayama H, Yamazaki M, Ueda M, et al. Low myocardial MIBG uptake in multiple system atrophy with incidental Lewy body pathology: An autopsy case report. Mov Disord. 2008; 23: 1055-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp